Stryker Co. (NYSE:SYK) Shares Sold by Long Road Investment Counsel LLC

Long Road Investment Counsel LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,025 shares of the medical technology company’s stock after selling 100 shares during the period. Stryker makes up about 6.2% of Long Road Investment Counsel LLC’s holdings, making the stock its 3rd biggest position. Long Road Investment Counsel LLC’s holdings in Stryker were worth $15,131,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. GSA Capital Partners LLP acquired a new stake in shares of Stryker in the 3rd quarter worth approximately $362,000. Empowered Funds LLC lifted its stake in shares of Stryker by 6.5% during the 3rd quarter. Empowered Funds LLC now owns 6,504 shares of the medical technology company’s stock worth $2,350,000 after purchasing an additional 399 shares during the period. Atlanta Consulting Group Advisors LLC purchased a new position in shares of Stryker during the 3rd quarter worth $256,000. Thrivent Financial for Lutherans increased its holdings in shares of Stryker by 6.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 93,239 shares of the medical technology company’s stock worth $33,683,000 after buying an additional 5,995 shares during the last quarter. Finally, Aljian Capital Management LLC increased its holdings in shares of Stryker by 6.1% during the 3rd quarter. Aljian Capital Management LLC now owns 12,605 shares of the medical technology company’s stock worth $4,554,000 after buying an additional 722 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Trading Up 1.1 %

Shares of NYSE:SYK opened at $373.65 on Tuesday. The firm has a fifty day moving average of $383.29 and a two-hundred day moving average of $373.71. The firm has a market capitalization of $142.58 billion, a P/E ratio of 48.15, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm posted $3.46 earnings per share. On average, equities analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SYK shares. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Truist Financial increased their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Finally, Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.